Crispr Therapeutics Stock: Bull vs. Bear
Crispr Therapeutics (NASDAQ: CRSP) may be about to prove the strength of its gene-editing technology. The biotech company is submitting its candidate to treat blood disorders to regulators in the U.S., Europe, and the U.K. this month. If regulators give Crispr the nod, it may soon reach the major milestone of product commercialization. And that will equal product revenue.
But is now really the moment to buy shares of this innovative company? Motley Fool contributors Adria Cimino and George Budwell present the bull and bear cases.
Adria Cimino: Crispr Therapeutics is heading for its big moment. The gene-editing specialist and its partner Vertex Pharmaceuticals are submitting exagamglogene autotemcel (aka exa-cel) to regulators as of this month. They expect to complete the U.S. submission in the first quarter of next year -- and submissions in the U.K. and Europe should be complete by the end of this year.
Source Fool.com
